A New Study to Test the Effectiveness of a New Drug to Treat Kidney Cancer

A New Study to Test the Effectiveness of a New Drug to Treat Kidney Cancer (Acceleron A041-04)

Official Title of Study: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma 

Objective of the study (lay terms): A new study to test the effectiveness of new cancer drug, Dalantercept, in combination with Axitinib compared to Axitinib alone 

For More Detailed Information, Contact:

• Alexandra Drakaki, MD, Principal Investigator, Assistant Professor of UCLA Urology and Hematology / Oncology
• Study Coordinator, 310-794-5418 or 310-794-7787, UCLA Department of Hematology-Oncology